Possible factors predictive of clinical relapse after stopping NA therapy
| Host factor | Age Specific genetic and immune markers |
| Virus factor | HBV genotype Baseline serum HBV DNA level Baseline serum HBsAg level Serum HBsAg level at the end of therapy Serum HBcrAg level at the end of therapy Serum HBV RNA at the end of therapy |
| Treatment factor | Treatment or consolidation duration Time to undetectable serum HBV DNA Duration of viral suppression under NA Type of NA (TDF vs ETV) |
ETV, entecavir; HBcrAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue; TDF, tenofovir disoproxil fumarate.